MAAT PHARMA | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
MAAT PHARMA

BRIEF

published on 11/21/2025 at 11:27, 13 days 17 hours ago

Crossing Thresholds at MAAT PHARMA

Voting Rights Capital Increase Crossing Thresholds MaaT Pharma Invus Public Equities
BRIEF

published on 11/19/2025 at 11:16, 15 days 18 hours ago

MaaT Pharma Secures Capital to Support Commercialization Efforts

Capital Increase MaaT Pharma Biotech Investment Xervyteg AGvHD Treatment
PRESS RELEASE

published on 11/19/2025 at 11:11, 15 days 18 hours ago

Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for MaaT Pharma SACA, citing successful €9.1m capital raise with strong investor support for lead drug Xervyteg. Company well-positioned for commercialization

First Berlin Equity Research Capital Increase Investment Advice Xervyteg MaaT Pharma SACA
BRIEF

published on 11/14/2025 at 23:10, 20 days 6 hours ago

MaaT Pharma: successful fundraising of 9.1 million euros

Investors Biotechnology Fundraising Microbiome Medical Innovation
PRESS RELEASE

published on 11/14/2025 at 23:05, 20 days 6 hours ago

Inside Information / Operations of the issuer (acquisitions, sales...)
MaaT Pharma successfully completes Global Offering of €9.1 million, strengthening financial position and supporting development of Microbiome Therapies for cancer patients

Financial Position Global Offering MaaT Pharma Cancer Patients Microbiome Therapies
BRIEF

published on 11/13/2025 at 19:45, 21 days 9 hours ago

MaaT Pharma launches a capital increase

Capital Increase Qualified Investors MaaT Pharma Global Offer Xervyteg® Marketing
PRESS RELEASE

published on 11/13/2025 at 19:40, 21 days 9 hours ago

Inside Information / Other news releases
MaaT Pharma launches a capital increase of approximately €9 million through a private placement and PrimaryBid offering. Funds raised to support Xervyteg® commercialization and extend cash runway until summer 2026

Private Placement Investment Capital Increase MaaT Pharma Xervyteg
BRIEF

published on 11/05/2025 at 07:35, 29 days 21 hours ago

MaaT Pharma Reveals Promising Preclinical Data for MaaT034

Cancer Treatment Immunotherapy MaaT Pharma Microbiome Therapy MaaT034
PRESS RELEASE

published on 11/05/2025 at 07:30, 29 days 21 hours ago

Inside Information / Other news releases
MaaT Pharma presents updated preclinical data for MaaT034, showing immune activation and anti-tumor activity at SITC Annual Meeting. New findings enhance patient responses to immunotherapy

Preclinical Data MaaT Pharma SITC Annual Meeting Immune Activation Anti-tumor Activity
BRIEF

published on 11/04/2025 at 11:43, 1 month ago

MaaT Pharma Receives BUY Rating from First Berlin Equity Research

Biotechnology Clinical Trials Investment Cancer Treatment Microbiome Therapy

1 2 ... 4

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 47 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 52 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 22 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 17 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 22 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 51 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 31 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 56 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 6 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 11 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 22 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 37 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 37 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 21 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE